Summary & Overview
HCPCS Q5157: Denosumab (biosimilar) Injection, 1 mg
HCPCS Level II code Q5157 designates a 1 mg unit of the denosumab biosimilar marketed as stoboclo/osenvelt for subcutaneous injection. Denosumab is used in clinical settings that involve modulation of bone metabolism, and the availability of a biosimilar formulation has implications for cost, access, and formulary placement nationally. This code matters as biosimilar adoption can influence payer coverage policies, provider billing practices, and patient out-of-pocket costs.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for denosumab biosimilars, typical sites of service where the product is administered, and the practical use of the HCPCS Level II code for claims. The publication provides benchmarking context, common billing modifiers and service-line considerations, and notes on payer coverage patterns and policy drivers where data is available. If specific payer policy details or diagnosis mappings are not present in the source, those items are noted as not available. The material is intended to aid billing managers, revenue cycle staff, and policy analysts in understanding the national significance and administrative handling of HCPCS Level II code Q5157.
Billing Code Overview
HCPCS Level II code Q5157 describes Injection, denosumab-bmwo (stoboclo/osenvelt), biosimilar, 1 mg. This code represents a single-unit measure of the biosimilar formulation of denosumab used for subcutaneous injection. Service type: injectable biological drug administration (denosumab biosimilar). Typical site of service: outpatient infusion/ambulatory clinic or physician office where injectable biologics are administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a postmenopausal woman or an adult patient with osteoporosis at high risk for fracture who presents to an outpatient infusion or injectable clinic for administration of a subcutaneous injection of denosumab-bmwo (Q5157), a biosimilar denosumab product. The patient has a prior evaluation by an endocrinologist, rheumatologist, or primary care provider documenting low bone mineral density (DEXA T-score ≤ -2.5) or a history of osteoporotic fracture and a decision to initiate monoclonal antibody therapy.
The clinical workflow begins with pre-procedure verification of indication, review of renal function and calcium levels, and confirmation of any contraindications (hypocalcemia, pregnancy). The clinic performs medication reconciliation and documents informed consent. The Q5157 product is supplied in a prefilled syringe or vial and is administered subcutaneously (commonly in the upper arm, thigh, or abdomen). Monitoring for immediate post-injection reactions is performed for 15–30 minutes. The visit is documented with drug name and biosimilar identifier, dose per billing unit, route, site of administration, lot number, and patient response. Follow-up scheduling for the next dose (typically every 6 months for denosumab) and management of calcium/vitamin D supplementation are documented.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |